JOONGANG ADVANCED MATERIALS Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Incheol Jeong

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.3yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

JOONGANG ADVANCED MATERIALS Co., Ltd's (KOSDAQ:051980) Shares Climb 32% But Its Business Is Yet to Catch Up

Apr 11

JOONGANG ADVANCED MATERIALS (KOSDAQ:051980) Is Looking To Continue Growing Its Returns On Capital

Apr 01

JOONGANG ADVANCED MATERIALS Co., Ltd's (KOSDAQ:051980) Shares Climb 37% But Its Business Is Yet to Catch Up

Feb 26

Investors Who Bought CentralBio (KOSDAQ:051980) Shares A Year Ago Are Now Up 369%

Dec 18

CEO

Incheol Jeong

7.3yrs

Tenure

Incheol Jeong serves as Chief Executive Officer at JOONGANG ADVANCED MATERIALS Co., Ltd (formerly known as JOONGANG DNM Co.,Ltd) (formerly known as CentralBio Co., Ltd.) and as its Representative Director...

JOONGANG ADVANCED MATERIALS Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

Less than half of directors are independent

Recent updates

JOONGANG ADVANCED MATERIALS Co., Ltd's (KOSDAQ:051980) Shares Climb 32% But Its Business Is Yet to Catch Up

JOONGANG ADVANCED MATERIALS (KOSDAQ:051980) Is Looking To Continue Growing Its Returns On Capital

JOONGANG ADVANCED MATERIALS Co., Ltd's (KOSDAQ:051980) Shares Climb 37% But Its Business Is Yet to Catch Up

New major risk - Share price stability

New major risk - Negative shareholders equity

JOONGANG DNM Co.,Ltd announced that it has received KRW 19.9975 billion in funding from Kwangmu Co.,Ltd.

JOONGANG DNM Co.,Ltd announced that it expects to receive KRW 22 billion in funding from Enchem Co., Ltd.

JOONGANG DNM Co.,Ltd announced that it expects to receive KRW 4.9997 billion in funding from GP Club Co., Ltd.

JOONGANG DNM Co.,Ltd announced that it has received KRW 5 billion in funding from HF Networks Co., Ltd.

Less than half of directors are independent

JOONGANG DNM Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.9995 million.

Less than half of directors are independent

Full year 2021 earnings released: ₩234 loss per share (vs ₩252 loss in FY 2020)

JOONGANG DNM Co.,Ltd announced that it expects to receive KRW 20 billion in funding from Caelum Partners Co., Ltd. and another investor

CentralBio Co., Ltd. announced that it has received KRW 6.26 billion in funding from HF Networks Co., Ltd.

New 90-day low: ₩1,580

New 90-day high: ₩3,140

Investors Who Bought CentralBio (KOSDAQ:051980) Shares A Year Ago Are Now Up 369%

New 90-day high: ₩2,170

CentralBio Co., Ltd announced that it has received KRW 13.1 billion in funding from Prime No. 1 Fund

New 90-day high: ₩1,995

An unknown buyer acquired 10.1% stake in CentralBio Co., Ltd (KOSDAQ:A051980) from Data Core ZenHealth Co., Ltd for KRW 4.5 billion.

CentralBio Co., Ltd announced that it has received KRW 8.8 billion in funding from Ilias Biologics

HJH Holdings Co., Ltd. and Aview Global Co., Ltd completed the acquisition of 16.15% stake in Barun Technology Co.,Ltd. (KOSDAQ:A029480) from CentralBio Co., Ltd (KOSDAQ:A051980).

CentralBio Co., Ltd announced that it expects to receive KRW 6.26 billion in funding from TYECO Co., Ltd.

New 90-day high - ₩765

CEO

Tenure